5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cardiac O
Toxicities O
: O
Monitor O
for O
signs O
and O
symptoms O
of O
cardiac O
failure O
or O
ischemia O
. O

Withhold O
Kyprolis O
and O
evaluate O
promptly O
. O

( O
5.1 O
) O
* O
Acute O
Renal O
Failure O
: O
Monitor O
serum O
creatinine O
regularly O
. O

( O
5.2 O
) O
* O
Tumor O
Lysis O
Syndrome O
( O
TLS O
) O
: O
Administer O
pre-treatment O
hydration O
. O

( O
2.1 O
) O
Monitor O
for O
TLS O
, O
including O
uric O
acid O
levels O
and O
treat O
promptly O
. O

( O
5.3 O
) O
* O
Pulmonary O
Toxicity O
, O
including O
Acute O
Respiratory O
Distress O
Syndrome O
, O
Acute O
Respiratory O
Failure O
, O
and O
Acute O
Diffuse O
Infiltrative O
Pulmonary O
Disease O
: O
Withhold O
Kyprolis O
and O
evaluate O
promptly O
. O

( O
5.4 O
) O
* O
Pulmonary O
Hypertension O
: O
Withhold O
Kyprolis O
and O
evaluate O
. O

( O
5.5 O
) O
* O
Dyspnea O
: O
For O
severe O
or O
life O
threatening O
dyspnea O
, O
withhold O
Kyprolis O
and O
evaluate O
. O

( O
5.6 O
) O
* O
Hypertension O
Including O
Hypertensive O
Crisis O
: O
Monitor O
blood O
pressure O
regularly O
. O

If O
hypertension O
can O
not O
be O
controlled O
, O
interrupt O
treatment O
with O
Kyprolis O
. O

( O
5.7 O
) O
* O
Venous O
Thrombosis O
: O
Thromboprophylaxis O
is O
recommended O
. O

( O
5.8 O
) O
* O
Infusion O
Reactions O
: O
Premedicate O
with O
dexamethasone O
. O

( O
2.1 O
, O
5.9 O
) O
* O
Hemorrhage O
: O
Fatal O
or O
serious O
cases O
of O
hemorrhage O
may O
occur O
, O
including O
gastrointestinal O
, O
pulmonary O
, O
and O
intracranial O
hemorrhage O
. O

Promptly O
evaluate O
signs O
and O
symptoms O
of O
blood O
loss O
. O

( O
5.10 O
) O
* O
Thrombocytopenia O
: O
Monitor O
platelet O
counts O
; O
interrupt O
or O
reduce O
Kyprolis O
dosing O
as O
clinically O
indicated O
. O

( O
2.3 O
, O
5.11 O
) O
* O
Hepatic O
Toxicity O
and O
Hepatic O
Failure O
: O
Monitor O
liver O
enzymes O
regularly O
. O

Withhold O
Kyprolis O
if O
suspected O
. O

( O
5.12 O
) O
* O
Thrombotic O
Microangiopathy O
: O
Monitor O
for O
signs O
and O
symptoms O
. O

Discontinue O
Kyprolis O
if O
suspected O
. O

( O
5.13 O
) O
* O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
( O
PRES O
) O
: O
Consider O
neuro-radiological O
imaging O
( O
MRI O
) O
for O
onset O
of O
visual O
or O
neurological O
symptoms O
; O
discontinue O
Kyprolis O
if O
suspected O
. O

( O
5.14 O
) O
* O
Increased O
Fatal O
and O
Serious O
Toxicites O
in O
Combination O
with O
Melphalan O
and O
Prednisone O
in O
Newly O
Diagnosed O
Transplant-Ineligible O
Patients O
( O
5.15 O
) O
* O
Embryo-Fetal O
Toxicity O
: O
Kyprolis O
can O
cause O
fetal O
harm O
. O

Females O
of O
reproductive O
potential O
should O
avoid O
becoming O
pregnant O
while O
being O
treated O
. O

( O
5.16 O
, O
8.1 O
) O
5.1 O
Cardiac B-OSE_Labeled_AE
Toxicities I-OSE_Labeled_AE
New O
onset O
or O
worsening O
of O
pre-existing O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
e.g. O
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
) O
, O
restrictive B-OSE_Labeled_AE
cardiomyopathy I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
and O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
including O
fatalities B-NonOSE_AE
have O
occurred O
following O
administration O
of O
Kyprolis O
. O

Some O
events O
occurred O
in O
patients O
with O
normal O
baseline O
ventricular O
function O
. O

In O
clinical O
studies O
with O
Kyprolis O
, O
these O
events O
occurred O
throughout O
the O
course O
of O
Kyprolis O
therapy O
. O

Death B-NonOSE_AE
due O
to O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
has O
occurred O
within O
one O
day O
of O
Kyprolis O
administration O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
evaluating O
Kyprolis O
in O
combination O
with O
lenalidomide O
and O
dexamethasone O
( O
KRd O
) O
versus O
lenalidomide/dexamethasone O
( O
Rd O
) O
, O
the O
incidence O
of O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
6 O
% O
in O
the O
KRd O
arm O
versus O
4 O
% O
in O
the O
Rd O
arm O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
of O
Kyprolis O
plus O
dexamethasone O
( O
Kd O
) O
versus O
bortezomib O
plus O
dexamethasone O
( O
Vd O
) O
, O
the O
incidence O
of O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
8 O
% O
in O
the O
Kd O
arm O
versus O
3 O
% O
in O
the O
Vd O
arm O
. O

Monitor O
patients O
for O
clinical O
signs O
or O
symptoms O
of O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
or O
cardiac B-NonOSE_AE
ischemia I-NonOSE_AE
. O

Evaluate O
promptly O
if O
cardiac B-NonOSE_AE
toxicity I-NonOSE_AE
is O
suspected O
. O

Withhold O
Kyprolis O
for O
Grade O
3 O
or O
4 O
cardiac B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
until O
recovery O
, O
and O
consider O
whether O
to O
restart O
Kyprolis O
at O
1 O
dose O
level O
reduction O
based O
on O
a O
benefit/risk O
assessment O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

While O
adequate O
hydration O
is O
required O
prior O
to O
each O
dose O
in O
Cycle O
1 O
, O
all O
patients O
should O
also O
be O
monitored O
for O
evidence O
of O
volume B-NonOSE_AE
overload I-NonOSE_AE
, O
especially O
patients O
at O
risk O
for O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
. O

Adjust O
total O
fluid O
intake O
as O
clinically O
appropriate O
in O
patients O
with O
baseline O
cardiac B-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
who O
are O
at O
risk O
for O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

In O
patients O
> O
= O
75 O
years O
of O
age O
, O
the O
risk O
of O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
is O
increased O
compared O
to O
patients O
Ë‚ O
75 O
years O
of O
age O
. O

Patients O
with O
New B-Not_AE_Candidate
York I-Not_AE_Candidate
Heart I-Not_AE_Candidate
Association I-Not_AE_Candidate
Class I-Not_AE_Candidate
III I-Not_AE_Candidate
and O
IV O
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
recent O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
conduction B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
angina B-Not_AE_Candidate
, O
or O
arrhythmias B-Not_AE_Candidate
uncontrolled O
by O
medications O
were O
not O
eligible O
for O
the O
clinical O
trials O
. O

These O
patients O
may O
be O
at O
greater O
risk O
for O
cardiac B-NonOSE_AE
complications I-NonOSE_AE
and O
should O
have O
a O
comprehensive O
medical O
assessment O
( O
including O
blood O
pressure O
and O
fluid O
management O
) O
prior O
to O
starting O
treatment O
with O
Kyprolis O
and O
remain O
under O
close O
follow-up O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

5.2 O
Acute O
Renal O
Failure O
Cases O
of O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
have O
occurred O
in O
patients O
receiving O
Kyprolis O
. O

Renal B-OSE_Labeled_AE
insufficiency I-OSE_Labeled_AE
adverse O
events O
( O
including O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
) O
have O
occurred O
in O
approximately O
10 O
% O
of O
patients O
treated O
with O
Kyprolis O
. O

Acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
reported O
more O
frequently O
in O
patients O
with O
advanced O
relapsed O
and O
refractory O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
who O
received O
Kyprolis O
monotherapy O
. O

This O
risk O
was O
greater O
in O
patients O
with O
a O
baseline O
reduced B-Not_AE_Candidate
estimated I-Not_AE_Candidate
creatinine I-Not_AE_Candidate
clearance I-Not_AE_Candidate
( O
calculated O
using O
Cockcroft O
and O
Gault O
equation O
) O
. O

Monitor O
renal O
function O
with O
regular O
measurement O
of O
the O
serum O
creatinine O
and/or O
estimated O
creatinine O
clearance O
. O

Reduce O
or O
withhold O
dose O
as O
appropriate O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.3 O
Tumor O
Lysis O
Syndrome O
Cases O
of O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TLS I-OSE_Labeled_AE
) O
, O
including O
fatal B-NonOSE_AE
outcomes O
, O
have O
been O
reported O
in O
patients O
who O
received O
Kyprolis O
. O

Patients O
with O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
and O
a O
high O
tumor B-Not_AE_Candidate
burden I-Not_AE_Candidate
should O
be O
considered O
to O
be O
at O
greater O
risk O
for O
TLS B-OSE_Labeled_AE
. O

Ensure O
that O
patients O
are O
well O
hydrated O
before O
administration O
of O
Kyprolis O
in O
Cycle O
1 O
, O
and O
in O
subsequent O
cycles O
as O
needed O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

Consider O
uric O
acid-lowering O
drugs O
in O
patients O
at O
risk O
for O
TLS B-NonOSE_AE
. O

Monitor O
for O
evidence O
of O
TLS O
during O
treatment O
and O
manage O
promptly O
, O
including O
interruption O
of O
Kyprolis O
until O
TLS O
is O
resolved O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

5.4 O
Pulmonary O
Toxicity O
Acute B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Distress I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ARDS I-OSE_Labeled_AE
) O
, O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
acute B-OSE_Labeled_AE
diffuse I-OSE_Labeled_AE
infiltrative I-OSE_Labeled_AE
pulmonary I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
such O
as O
pneumonitis B-OSE_Labeled_AE
and O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
have O
occurred O
in O
less O
than O
1 O
% O
of O
patients O
receiving O
Kyprolis O
. O

Some O
events O
have O
been O
fatal B-NonOSE_AE
. O

In O
the O
event O
of O
drug-induced O
pulmonary B-NonOSE_AE
toxicity I-NonOSE_AE
, O
discontinue O
Kyprolis O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.5 O
Pulmonary O
Hypertension O
Pulmonary B-OSE_Labeled_AE
arterial I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
was O
reported O
in O
approximately O
1 O
% O
of O
patients O
treated O
with O
Kyprolis O
and O
was O
Grade O
3 O
or O
greater O
in O
less O
than O
1 O
% O
of O
patients O
. O

Evaluate O
with O
cardiac O
imaging O
and/or O
other O
tests O
as O
indicated O
. O

Withhold O
Kyprolis O
for O
pulmonary B-NonOSE_AE
hypertension I-NonOSE_AE
until O
resolved O
or O
returned O
to O
baseline O
, O
and O
consider O
whether O
to O
restart O
Kyprolis O
based O
on O
a O
benefit/risk O
assessment O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.6 O
Dyspnea O
Dyspnea B-OSE_Labeled_AE
was O
reported O
in O
28 O
% O
of O
patients O
treated O
with O
Kyprolis O
and O
was O
Grade O
3 O
or O
greater O
in O
4 O
% O
of O
patients O
. O

Evaluate O
dyspnea B-NonOSE_AE
to O
exclude O
cardiopulmonary B-NonOSE_AE
conditions I-NonOSE_AE
including O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
and O
pulmonary B-NonOSE_AE
syndromes I-NonOSE_AE
. O

Stop O
Kyprolis O
for O
Grade O
3 O
or O
4 O
dyspnea B-NonOSE_AE
until O
resolved O
or O
returned O
to O
baseline O
. O

Consider O
whether O
to O
restart O
Kyprolis O
based O
on O
a O
benefit/risk O
assessment O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
and O
5.4 O
) O
, O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.7 O
Hypertension O
Hypertension B-OSE_Labeled_AE
, O
including O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
and O
hypertensive B-OSE_Labeled_AE
emergency I-OSE_Labeled_AE
, O
has O
been O
observed O
with O
Kyprolis O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
evaluating O
Kyprolis O
in O
combination O
with O
KRd O
versus O
Rd O
, O
the O
incidence O
of O
hypertension B-OSE_Labeled_AE
events O
was O
16 O
% O
in O
the O
KRd O
arm O
versus O
8 O
% O
in O
the O
Rd O
arm O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
of O
Kd O
versus O
Vd O
, O
the O
incidence O
of O
hypertension B-OSE_Labeled_AE
events O
was O
26 O
% O
in O
the O
Kd O
arm O
versus O
10 O
% O
in O
the O
Vd O
arm O
. O

Some O
of O
these O
events O
have O
been O
fatal B-NonOSE_AE
. O

Monitor O
blood O
pressure O
regularly O
in O
all O
patients O
. O

If O
hypertension B-NonOSE_AE
can O
not O
be O
adequately O
controlled O
, O
withhold O
Kyprolis O
and O
evaluate O
. O

Consider O
whether O
to O
restart O
Kyprolis O
based O
on O
a O
benefit/risk O
assessment O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

5.8 O
Venous O
Thrombosis O
Venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
including O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
have O
been O
observed O
with O
Kyprolis O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
evaluating O
KRd O
versus O
Rd O
( O
with O
thromboprophylaxis O
used O
in O
both O
arms O
) O
, O
the O
incidence O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
first O
12 O
cycles O
was O
13 O
% O
in O
the O
KRd O
arm O
versus O
6 O
% O
in O
the O
Rd O
arm O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
of O
Kd O
versus O
Vd O
, O
the O
incidence O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
months O
1-6 O
was O
9 O
% O
in O
the O
Kd O
arm O
versus O
2 O
% O
in O
the O
Vd O
arm O
. O

With O
Kyprolis O
monotherapy O
, O
the O
incidence O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
2 O
% O
. O

Thromboprophylaxis O
is O
recommended O
for O
patients O
being O
treated O
with O
the O
combination O
of O
Kyprolis O
with O
dexamethasone O
or O
with O
lenalidomide O
plus O
dexamethasone O
. O

The O
thromboprophylaxis O
regimen O
should O
be O
based O
on O
an O
assessment O
of O
the O
patient O
's O
underlying O
risks O
. O

Patients O
using O
oral O
contraceptives O
or O
a O
hormonal O
method O
of O
contraception O
associated O
with O
a O
risk O
of O
thrombosis B-NonOSE_AE
should O
consider O
an O
alternative O
method O
of O
effective O
contraception O
during O
treatment O
with O
Kyprolis O
in O
combination O
with O
dexamethasone O
or O
lenalidomide O
plus O
dexamethasone O
[ O
see O
Use O
in O
Specific O
Population O
( O
8.3 O
) O
] O
. O

5.9 O
Infusion O
Reactions O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
life-threatening O
reactions O
, O
have O
occurred O
in O
patients O
receiving O
Kyprolis O
. O

Symptoms O
include O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
facial B-NonOSE_AE
flushing I-NonOSE_AE
, O
facial B-NonOSE_AE
edema I-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
chest B-NonOSE_AE
tightness I-NonOSE_AE
, O
or O
angina B-NonOSE_AE
. O

These O
reactions O
can O
occur O
immediately O
following O
or O
up O
to O
24 O
hours O
after O
administration O
of O
Kyprolis O
. O

Administer O
dexamethasone O
prior O
to O
Kyprolis O
to O
reduce O
the O
incidence O
and O
severity O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

Inform O
patients O
of O
the O
risk O
and O
of O
symptoms O
and O
to O
contact O
a O
physician O
immediately O
if O
symptoms O
of O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
occur O
. O

5.10 O
Hemorrhage O
Fatal B-NonOSE_AE
or O
serious O
cases O
of O
hemorrhage B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Kyprolis O
. O

Hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
included O
gastrointestinal B-OSE_Labeled_AE
, O
pulmonary O
, O
and O
intracranial O
hemorrhage I-OSE_Labeled_AE
and O
epistaxis B-OSE_Labeled_AE
. O

The O
bleeding B-OSE_Labeled_AE
can O
be O
spontaneous O
, O
and O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
has O
occurred O
without O
trauma O
. O

Hemorrhage B-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
having O
either O
low B-Not_AE_Candidate
or O
normal O
platelet I-Not_AE_Candidate
counts I-Not_AE_Candidate
. O

Hemorrhage B-OSE_Labeled_AE
has O
also O
been O
reported O
in O
patients O
who O
were O
not O
on O
antiplatelet O
therapy O
or O
anticoagulation O
. O

Promptly O
evaluate O
signs O
and O
symptoms O
of O
blood B-NonOSE_AE
loss I-NonOSE_AE
. O

Reduce O
or O
withhold O
dose O
as O
appropriate O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.11 O
Thrombocytopenia O
Kyprolis O
causes O
thrombocytopenia B-OSE_Labeled_AE
with O
platelet O
nadirs O
observed O
between O
Day O
8 O
and O
Day O
15 O
of O
each O
28-day O
cycle O
, O
with O
recovery O
to O
baseline O
platelet O
count O
usually O
by O
the O
start O
of O
the O
next O
cycle O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Thrombocytopenia B-OSE_Labeled_AE
was O
reported O
in O
approximately O
40 O
% O
of O
patients O
in O
clinical O
trials O
with O
Kyprolis O
. O

Monitor O
platelet O
counts O
frequently O
during O
treatment O
with O
Kyprolis O
. O

Reduce O
or O
withhold O
dose O
as O
appropriate O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Hemorrhage B-OSE_Labeled_AE
may O
occur O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

5.12 O
Hepatic O
Toxicity O
and O
Hepatic O
Failure O
Cases O
of O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
cases O
, O
have O
been O
reported O
( O
< O
1 O
% O
) O
during O
treatment O
with O
Kyprolis O
. O

Kyprolis O
can O
cause O
increased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
. O

Monitor O
liver O
enzymes O
regularly O
, O
regardless O
of O
baseline O
values O
. O

Reduce O
or O
withhold O
dose O
as O
appropriate O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.13 O
Thrombotic O
Microangiopathy O
Cases O
of O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
, O
including O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
/ O
hemolytic B-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
TTP B-OSE_Labeled_AE
/ O
HUS B-OSE_Labeled_AE
) O
, O
have O
been O
reported O
in O
patients O
who O
received O
Kyprolis O
. O

Some O
of O
these O
events O
have O
been O
fatal B-NonOSE_AE
. O

Monitor O
for O
signs O
and O
symptoms O
of O
TTP B-NonOSE_AE
/ O
HUS B-NonOSE_AE
. O

If O
the O
diagnosis O
is O
suspected O
, O
stop O
Kyprolis O
and O
evaluate O
. O

If O
the O
diagnosis O
of O
TTP B-NonOSE_AE
/ O
HUS B-NonOSE_AE
is O
excluded O
, O
Kyprolis O
may O
be O
restarted O
. O

The O
safety O
of O
reinitiating O
Kyprolis O
therapy O
in O
patients O
previously O
experiencing O
TTP B-NonOSE_AE
/ O
HUS B-NonOSE_AE
is O
not O
known O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.14 O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
Cases O
of O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
receiving O
Kyprolis O
. O

PRES B-NonOSE_AE
, O
formerly O
termed O
Reversible B-NonOSE_AE
Posterior I-NonOSE_AE
Leukoencephalopathy I-NonOSE_AE
Syndrome I-NonOSE_AE
( I-NonOSE_AE
RPLS I-NonOSE_AE
) O
, O
is O
a O
neurological B-NonOSE_AE
disorder I-NonOSE_AE
which O
can O
present O
with O
seizure B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
, O
altered B-NonOSE_AE
consciousness I-NonOSE_AE
, O
and O
other O
visual B-NonOSE_AE
and O
neurological O
disturbances I-NonOSE_AE
, O
along O
with O
hypertension B-NonOSE_AE
, O
and O
the O
diagnosis O
is O
confirmed O
by O
neuro-radiological O
imaging O
( O
MRI O
) O
. O

Discontinue O
Kyprolis O
if O
PRES B-NonOSE_AE
is O
suspected O
and O
evaluate O
. O

The O
safety O
of O
reinitiating O
Kyprolis O
therapy O
in O
patients O
previously O
experiencing O
PRES B-NonOSE_AE
is O
not O
known O
. O

5.15 O
Increased O
Fatal O
and O
Serious O
Toxicities O
in O
Combination O
with O
Melphalan O
and O
Prednisone O
in O
Newly O
Diagnosed O
Transplant-Ineligible O
Patients O
In O
a O
clinical O
trial O
of O
955 O
transplant-ineligible O
patients O
with O
newly O
diagnosed O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
randomized O
to O
Kyprolis O
( O
20/36 O
mg/m O
2 O
by O
30-minute O
infusion O
twice O
weekly O
for O
four O
of O
each O
six-week O
cycle O
) O
, O
melphalan O
and O
prednisone O
( O
KMP O
) O
or O
bortezomib O
, O
melphalan O
and O
prednisone O
( O
VMP O
) O
, O
a O
higher O
incidence O
of O
fatal B-NonOSE_AE
adverse O
reactions O
( O
7 O
% O
versus O
4 O
% O
) O
and O
serious O
adverse O
reactions O
( O
50 O
% O
versus O
42 O
% O
) O
were O
observed O
in O
the O
KMP O
arm O
compared O
to O
patients O
in O
the O
VMP O
arm O
, O
respectively O
. O

Patients O
in O
the O
KMP O
arm O
were O
observed O
to O
have O
a O
higher O
incidence O
of O
any O
grade O
adverse O
reactions O
involving O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
11 O
% O
versus O
4 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
25 O
% O
versus O
8 O
% O
) O
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
14 O
% O
versus O
6 O
% O
) O
, O
and O
dyspnea B-OSE_Labeled_AE
( O
18 O
% O
versus O
9 O
% O
) O
. O

This O
study O
did O
not O
meet O
its O
primary O
outcome O
measure O
of O
superiority O
in O
progression-free O
survival O
for O
the O
KMP O
arm O
. O

Kyprolis O
in O
combination O
with O
melphalan O
and O
prednisone O
is O
not O
indicated O
for O
transplant-ineligible O
patients O
with O
newly O
diagnosed O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

5.16 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Kyprolis O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
based O
on O
its O
mechanism O
of O
action O
and O
findings O
in O
animals O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
using O
Kyprolis O
. O

Advise O
females O
of O
reproductive O
potential O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
while O
being O
treated O
with O
Kyprolis O
. O

Advise O
males O
of O
reproductive O
potential O
to O
avoid O
fathering O
a O
child O
while O
being O
treated O
with O
Kyprolis O
. O

Advise O
women O
who O
use O
Kyprolis O
during O
pregnancy B-Not_AE_Candidate
or O
become O
pregnant B-Not_AE_Candidate
during O
treatment O
with O
Kyprolis O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

